New Insights into Glioblastoma
Diagnosis, Therapeutics and Theranostics
- 1st Edition - May 17, 2023
- Imprint: Academic Press
- Editors: Carla Vitorino, Carmen Balana, Célia Cabral
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 8 7 3 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 9 4 2 - 7
New Insights into Glioblastoma: Diagnosis, Therapeutics and Theranostics provides a compendium of recent diagnostic and therapeutic advances in GBM, encompassing a pipeline… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNew Insights into Glioblastoma: Diagnosis, Therapeutics and Theranostics provides a compendium of recent diagnostic and therapeutic advances in GBM, encompassing a pipeline of compounds and (bio) nanotechnology strategies that have stood out with potential increased antitumoral activity and capability to cross the blood-brain barrier. Issues and challenges related to their translation into the clinical practice and their contribution to the increase in survival rates and well-being of patients are addressed. This is a valuable resource for graduate students, oncologists, cancer researchers and members of the biomedical field who need to learn more on recent developments on the management of glioblastoma.
The book is split in three parts: Diagnosis, focusing on biomarkers and techniques such PET/MRI, infrared thermography, and deep neural networks; Therapeutics, discussing new chemical entities, as natural products and repurposed drugs, and new formulation approaches, as nanotechnology-based and microRNA approaches; and Theranostics, explaining the role of omics, system-based approaches, and glioblastoma microenvironment.
- Provides guidance towards recent advances of new chemical entities and delivery strategies targeted to glioblastoma
- Includes overviews to help readers apply information in their research
- Encompasses summarizing diagrams and real-world examples to facilitate comprehension and enhance the applicability of the content
Graduate students and researchers on cancer/oncology, Graduate students and researchers on neuroscience and behavioral science
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Foreword
- Part I: Introduction
- Chapter 1: Introduction: A brief outlook into glioblastoma diagnosis and therapeutics
- 1.1: Introduction
- References
- Part II: Diagnosis
- Part II.1: Biomarkers
- Chapter 2: Practice guidelines for the diagnosis of glioblastoma
- Abstract
- 2.1: Introduction and historical perspective of high-grade gliomas
- 2.2: Glioblastoma and other high-grade gliomas. Current classification and genetic driver mutations
- 2.3: Glioblastoma, IDH-wildtype (IDHwt GB)
- 2.4: IDH-mutated gliomas
- 2.5: High-grade gliomas in pediatric, adolescent, and young adult populations
- 2.6: Molecular profiles and epigenetic studies applied to the diagnosis of glioblastoma
- 2.7: Recommended nomenclature for reporting glioblastoma and high-grade gliomas
- 2.8: Pathology of IDH-wt glioblastoma and diagnostic workup
- 2.9: Final remarks and future trends
- References
- Chapter 3: Identification of potential biomarkers in glioblastoma through omics technologies and big data analysis
- Abstract
- 3.1: Introduction
- 3.2: Biomarkers in disease management
- 3.3: Omics technologies in biomarker discovery and disease prognosis
- 3.4: The proteogenomics approach—A comprehensive view on data analysis
- 3.5: Global repositories of omics data
- 3.6: Challenges in multiomics data integration and future perspectives
- 3.7: Conclusions
- References
- Chapter 4: Forging a path to the use of liquid biopsy in the diagnosis of gliomas
- Abstract
- 4.1: Introduction
- 4.2: Molecular alterations useful for the diagnosis of glioblastoma
- 4.3: Liquid biopsy in cancer
- 4.4: Components of the liquid biopsy (Fig. 4.1)
- 4.5: Source of liquid biopsy: Blood or CSF
- 4.6: Applications of liquid biopsy in gliomas
- 4.7: Conclusions
- References
- Chapter 5: Secretome analysis of patient-derived glioblastoma cells for potential biomarker identification
- Abstract
- Acknowledgments
- 5.1: Introduction
- 5.2: Secretome, a source of circulating biomarkers
- 5.3: Glioblastoma circulating biomarkers: Review on potential candidates
- 5.4: Conclusions
- References
- Part II.2: Techniques: updates
- Chapter 6: Newly diagnosed glioblastoma: A review on clinical management
- Abstract
- 6.1: Introduction
- 6.2: Clinical presentation
- 6.3: Prognostic factors
- 6.4: Current standard treatment—An overview
- 6.5: Current management of elderly patients
- 6.6: Supportive care in GB patients
- 6.7: Conclusions
- References
- Chapter 7: Current status in brain glioblastoma imaging (MRI, CT-Scan)
- Abstract
- 7.1: Introduction
- 7.2: Neuroradiologic modalities in clinical approach to brain gliomas
- 7.3: Relevance of each sequence in the diagnostic approach of gliomas
- 7.4: Contribution of imaging in the diagnosis of glioblastoma
- 7.5: Role of imaging before and after surgery
- 7.6: After surgery
- 7.7: Conclusions
- References
- Chapter 8: Combined PET/MRI in brain glioma imaging
- Abstract
- 8.1: Introduction
- 8.2: Molecular imaging of gliomas
- 8.3: Magnetic resonance imaging
- 8.4: Combined studies
- 8.5: Combination of PET with spectroscopy
- 8.6: Improving confidence on inference in pathology
- 8.7: Conclusions
- References
- Chapter 9: New surgical approaches in glioblastoma
- Abstract
- 9.1: Introduction
- 9.2: The role of surgery in the treatment of glioblastoma
- 9.3: Imaging and planning
- 9.4: Brain mapping
- 9.5: Surgical techniques and improved efficiency
- 9.6: Surgery as an adjunct to other therapeutic modalities
- 9.7: Delivery of therapeutic agents
- 9.8: Surgical techniques based on physical properties
- 9.9: Ethical considerations on the surgical treatment of glioblastomas and innovation
- 9.10: Conclusions
- References
- Chapter 10: The role of radiogenomics
- Abstract
- 10.1: Introduction
- 10.2: MRI findings in glioblastoma
- 10.3: Genomics of glioblastoma
- 10.4: Radiogenomics of glioblastoma
- 10.5: Tumor imaging and gene expression profiles
- 10.6: Molecular characteristics and imaging signatures
- 10.7: Future directions
- 10.8: Conclusions
- References
- Part III: Therapeutics
- Part III.1: New chemical entities
- Chapter 11: An overview of molecular targeting of glioblastoma
- Abstract
- 11.1: Introduction
- 11.2: Targeted therapies in GB
- 11.3: Conclusions
- References
- Chapter 12: Terpenes: A hope for glioblastoma patients
- Abstract
- Conflict of interest
- 12.1: Introduction
- 12.2: Summary of the main antiglioblastoma mechanisms exerted by terpenes
- 12.3: Plant diterpenes against glioblastoma
- 12.4: Other plant-derived terpenes against glioblastoma
- 12.5: Other terpenes of natural origin
- 12.6: Conclusions
- References
- Chapter 13: Artificial intelligence to speed up active compounds screening
- Abstract
- Acknowledgments
- 13.1: Introduction
- 13.2: AI in drug screening
- 13.3: Virtual screening and DL to predict the most effective anticancer drugs
- 13.4: Conclusions
- References
- Chapter 14: Repurposing drugs in glioblastoma
- Abstract
- 14.1: Introduction
- 14.2: Repurposed drug subgroups
- 14.3: Conclusions
- References
- Chapter 15: Glioblastoma heterogeneity and resistance: A glance in biology and therapeutic approach
- Abstract
- 15.1: General introduction
- 15.2: Tumor heterogeneity
- 15.3: Single-cell analysis for detection of GB signatures
- 15.4: Targeting the blood-brain barrier
- 15.5: Targeting GB—Synthetic nanomedicine for GB treatment and diagnosis
- 15.6: Future considerations
- 15.7: Conclusions
- References
- Chapter 16: Targeting DNA damage response pathways in glioblastoma: From mechanistic insights to advances in the clinic
- Abstract
- 16.1: Introduction
- 16.2: Single-strand breaks repair
- 16.3: Double-strand breaks repair
- 16.4: Other inhibitory molecules to target DDR
- 16.5: New potential treatments and targets for DDR response inhibition
- 16.6: Conclusions
- References
- Chapter 17: Alkaloids: Their relevance in cancer treatment
- Abstract
- Acknowledgments
- 17.1: Introduction
- 17.2: Alkaloids in cancer treatment
- 17.3: Focusing on antiglioblastoma properties
- 17.4: Conclusions
- References
- Further reading
- Part III.2: New formulation approaches
- Chapter 18: An overview of current drug delivery strategies for glioblastoma treatment and barriers to progress
- Abstract
- Acknowledgments
- 18.1: Introduction
- 18.2: Local treatments
- 18.3: Nose to brain
- 18.4: Advanced drug delivery systems for systemic administration
- 18.5: Conclusions
- References
- Chapter 19: Nanotechnology-based approaches in glioblastoma treatment: How can the dual blood-brain/tumor barriers be overcome?
- Abstract
- 19.1: Introduction
- 19.2: Nanotechnology for drug delivery to the brain
- 19.3: Advanced biomimetic approaches for brain targeting
- 19.4: Conclusions
- References
- Chapter 20: Non-coding RNAs in glioblastoma at a glance
- Abstract
- 20.1: Introduction
- 20.2: Non-coding RNAs
- 20.3: Circular RNAs
- 20.4: Long non-coding RNAs
- 20.5: Conclusions
- References
- Chapter 21: The role of vaccines in glioblastoma—Updated clinical results
- Abstract
- 21.1: Introduction
- 21.2: Tumor antigen targets in glioblastoma
- 21.3: Combination therapy
- 21.4: Peptide vaccines
- 21.5: Dendritic cell vaccines
- 21.6: Viral-based vaccination approaches for treatment of glioblastoma
- 21.7: Future challenges
- References
- Chapter 22: Dendritic cells and glioblastoma
- Abstract
- 22.1: Introduction
- 22.2: Dendritic cell biology
- 22.3: Role of DC in glioma
- 22.4: DC-based therapeutic vaccine in glioblastoma
- 22.5: Targeting DCs in clinical trials
- 22.6: Limitations of DC-based vaccine
- References
- Chapter 23: Cancer stem cells in glioblastoma – an update
- Abstract
- 23.1: Introduction
- 23.2: Cancer stem cell hypothesis
- 23.3: Discovery of glioma cancer stem-like cells (GSCs)
- 23.4: Role of plasticity in tumor cellular heterogeneity
- 23.5: CSCs differentiate to form the bulk tumor cells
- 23.6: Differentiated cancer cells reprogram to form CSCs
- 23.7: Transdifferentiation—An added feather to the cap for tumor maintenance
- 23.8: Transdifferentiation of tumor cells into pericytes
- 23.9: Conclusions
- References
- Chapter 24: Optimizing the role of immunotherapy for the treatment of glioblastoma
- Abstract
- 24.1: Introduction
- 24.2: GB immune landscape
- 24.3: GB immunotherapies
- 24.4: Conclusions
- References
- Chapter 25: The role of exosomes in glioblastoma treatment
- Abstract
- Acknowledgments
- 25.1: Introduction
- 25.2: Exosomes
- 25.3: Exosome-based therapy for glioblastoma
- 25.4: Conclusions
- References
- Part IV: Theranostics
- Chapter 26: Theranostic in glioblastoma
- Abstract
- 26.1: Introduction
- 26.2: Targeting strategies
- 26.3: Challenges in GB theranostics
- 26.4: Conclusions
- References
- Further reading
- Chapter 27: Potential theranostic targets in glioblastoma
- Abstract
- 27.1: Introduction
- 27.2: Glioblastoma drug delivery challenge
- 27.3: Emerging nanomedicine approach in glioblastoma theranostics
- 27.4: Delivery of therapeutic agents via polymeric nanocarriers
- 27.5: Bioinspired-based theranostic for glioblastoma
- 27.6: Theranostic nanoparticles to enhance the response of GB to radiation
- 27.7: Clinical translation of nanomedicine in glioblastoma treatment
- 27.8: Conclusions
- References
- Chapter 28: Radiopharmaceuticals for molecular imaging and theranostics of glioblastoma
- Abstract
- Acknowledgments
- 28.1: Introduction
- 28.2: Nuclear medicine and radiopharmaceuticals
- 28.3: Design and preclinical evaluation of radiopharmaceuticals for GB targeting
- 28.4: Radioactive agents for imaging and theranostics of GB
- 28.5: Conclusions
- References
- Chapter 29: Theranostic strategies to potentiate glioblastoma treatment via nanotechnology: The example of gold nanoparticles
- Abstract
- Acknowledgments
- 29.1: Introduction
- 29.2: Hyperthermia at a glance
- 29.3: Photothermal therapy mediated by gold nanoparticles
- 29.4: Gold nanoparticles as theranostic agents
- 29.5: Conclusions
- References
- Chapter 30: The effect of glioblastoma microenvironment on therapeutic, diagnostic, or theranostic systems
- Abstract
- Acknowledgments
- 30.1: Background
- 30.2: Glioblastoma microenvironment features and envisaged impact on the fate of therapeutic, diagnostic, or theranostic systems—A potential threat
- 30.3: Harnessing glioblastoma microenvironment features to develop therapeutic, diagnostic, or theranostic precision systems—A window of opportunity
- 30.4: Conclusions
- References
- Index
- Edition: 1
- Published: May 17, 2023
- No. of pages (Paperback): 786
- No. of pages (eBook): 786
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323998734
- eBook ISBN: 9780323999427
CV
Carla Vitorino
Carla Vitorino is Assistant Professor at the Faculty of Pharmacy, University of Coimbra. in the Pharmaceutical Technology area and is an integrated researcher at the Coimbra Chemistry Centre, currently a part of the associate laboratory Institute of Molecular Sciences (IMS). Her research and development activities have been fundamentally directed towards three interrelated focal points:
(i) Scientific: The primary emphasis here pertains to the formulation of more effective strategies in conjunction with drug nanodelivery systems, tailored to address multipurpose requisites within unmet medical needs. Specifically, she has been working on the application of nanotechnology in drug permeation enhancement strategies for transdermal, oral, and drug delivery systems to brain targeting. Under the projects she has coordinated and co-coordinated, she has contributed to the development of advanced nanotechnological formulations, specifically tailored for brain targeting in the context of tumor treatment and diagnosis. Through the integration of in silico-in vitro-in vivo approaches, she has fostered the development of new treatment strategies for brain tumor patients and improved diagnosis, establishing the bridge between pharmaceutical research and clinical practice. Alternative routes to access brain (e.g. intranasal administration) for delivering drugs in a more efficient way have also been explored.
(ii) Industrial: This has been grounded on the systematic deployment of frameworks driven by a quality by design (QbD) philosophy, along with process analytical technology (PAT) tools. The central tenet lies in the application of structured approaches to the development of specific drug products, including but not limited to semi-solids and injectables. Concomitantly, in-line process control and monitoring mechanisms are incorporated.
(iii) Regulatory: This has been directed to the development of analytical protocols, elaborated as surrogate modalities for clinical trials. These protocols, addressing in vitro methodologies, are designed to facilitate the bioequivalence assessment of generic topical drug products, thus holding relevance in regulatory contexts.
Affiliations and expertise
Assistant Professor, Faculty of Pharmacy, University of Coimbra, Coimbra, PortugalCB
Carmen Balana
Carmen Balana created one of the first neuro-oncology committees in Spain and was a founder of the Spanish Neurooncological Group (now GEINO), where she was president and remain an active member. Her first publication as first author in a high-impact journal was in 2003 on liquid biopsies in high-grade gliomas, which has only recently become a strong research line. Other professional accomplishments: EORTC Brain Tumor Study Group (since 2002); reviewer and Editorial Committee member on several journals, including Neuro-Oncology; invited speaker at ESMO 2019 and ESMO ASIA 2020; President, IGTP Internal Scientific Committee (since 2017); President, Catalan-Balearic Oncology Society (since September 2020); PI, 70+ clinical trials (35 in CNS). She coordinated several ISCII grants and recently the Marató TV3 (665/C/2013) grant (1,690,500€), when she was able to coordinate six Catalan hospitals on a large clinical, radiological, immunohistochemical and molecular study of glioblastoma.
Affiliations and expertise
Catalan Institute of Oncology, Badalona/Barcelona, SpainCC
Célia Cabral
Célia Cabral graduated in Biology from the University of Coimbra and obtained her PhD in Biology, in the speciality of Systematics and Morphology, by the same institution, involving the Faculty of Sciences and Technology, the Faculty of Pharmacy and the Royal Botanic Garden Edinburgh (RBGE), UK. Between 2011 and 2017, Dr. Cabral did a 6-year post-doc at the Faculty of Pharmacy of UC. Currently, she is Researcher at the Faculty of Medicine of the University of Coimbra and Invited professor at the Universidade Lusófona. She has a multidisciplinary scientific path, with emphasis in Phytochemistry, Pharmacognosy, Natural products and Plant-based health solutions. Her main research interests are ethnopharmacology, phytochemistry, drug delivery of natural products, development of food supplements and natural products-based cosmetics.
Affiliations and expertise
Coimbra Institute for Clinical and Biomedical Research (iCBR), Center for Innovative Biomedicine and Biotechnology (CIBB), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, University of Coimbra, PortugalRead New Insights into Glioblastoma on ScienceDirect